Merck Flags Concerns on Widening Cancer Drug Trial Eligibility Criteria

Drug Industry Daily
A A
Merck urged the FDA to look into potential safety concerns as the agency seeks to widen patient eligibility criteria for oncology drug trials of HIV, hepatitis B and hepatitis C patients.

To View This Article:

Login

Subscribe To Drug Industry Daily